![](https://cdn.bluebirdbio.com/-/media/bluebirdbio/Corporate-COM/Images/Heros/Site-Refresh-Heroes/OurScienceMarquee.png?rev=eae14e099770464ca4bc5017c0c2bdc8&hash=E180EAC2C0983520CFFFC49CC13CB7AC)
ex-vivo gene therapy
data set in the world.
pipeline
clinical and pre-clinical research
- Pre-Clinical
- Phase 1
- Phase 2
- Phase 3
lovotibeglogene autotemcel gene therapy (lovo-cel; formerly LentiGlobinTM for sickle cell disease)
-
SCD (HGB-210)
-
SCD (HGB-206)
bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established.